Financial PerformanceRevenue continues to grow, with a 41% increase in NEXLETOL/NEXLIZET U.S. product revenue driven by retail prescription growth.
Market ExpansionEsperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada, highlighting its global expansion efforts.
Research And DevelopmentEsperion is expanding its early-stage development pipeline with a new program targeting primary sclerosing cholangitis (PSC).